2.35 Prescribing Practices of Antipsychotics in Children and Adolescents With a Diagnosis of Dmdd in an Outpatient Setting

• Published in: Journal of the American Academy of Child and Adolescent Psychiatry Vol. 57; no. 10; p. S170
• Main Authors: Walyzada, Frozan, Manocha, Pankaj, Odom, Charles, Badillo, Monica, Padilla, Felix Matos, Ahmad, Zaki, Sharha, Alaaddin, Korenis, Panagiota
• Format: Journal Article
• Language: English
• Published: Baltimore Elsevier Inc 01-10-2018; Elsevier BV
• Subjects: Adolescents; Aggressiveness; Antipsychotics; Aripiprazole; Attention deficit hyperactivity disorder; Child & adolescent psychiatry; Children; Children & youth; Clinical significance; Irritability; Medical diagnosis; Mental disorders; Outpatient care facilities; Prescribing; Prescription drugs; Risperidone; Teenagers; Tranquilizers
• ISSN: 0890-8567; 1527-5418
• DOI: 10.1016/j.jaac.2018.09.123

DMDD was first published in the DSM-5 in 2013, and currently, there are no established guidelines on how to treat it, as treatment depends on what symptom relief one seeks. Risperidone and aripiprazole are FDA-approved for children and adolescents that have irritability associated with ASD and has been used to treat DMDD in children and youth that involve physical aggression. A previous report showed clinically significant improvement in ADHD and depression symptoms, as well as in global functioning in an open-label study of youth diagnosed with DMDD on risperidone.